Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence | Zendy

J. Delaunay | Zendy; Ludovic Martin | Zendy; Brigitte Bressac–de Paillerets | Zendy; Gérard Duru | Zendy; Olivier Ingster | Zendy; L. Thomas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence

Author(s) -

J. Delaunay,

Ludovic Martin,

Brigitte Bressac–de Paillerets,

Gérard Duru,

Olivier Ingster,

L. Thomas

Publication year - 2017

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2017.2926

Subject(s) - medicine , cdkn2a , incidence (geometry) , genetic testing , retrospective cohort study , bap1 , melanoma , population , cohort , oncology , cancer , mutation , dermatology , genetics , gene , cancer research , physics , environmental health , optics , biology

Genetic testing for melanoma-prone mutation in France, a country with low to moderate incidence of melanoma, is proposed in cases with 2 invasive cutaneous melanomas and/or related cancers in the same patient, or in first- or second-degree relatives (rule of 2). In preclinical studies, these rules led to disclosure of mutation(s) in more than 10% of these families, the threshold widely accepted to justify genetic testing for cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research